In July Tricerion received funding from the UK Government’s Fast Start Competition to address COVID-19 Challenges. The competition aims to fast-track the development of innovations borne out of the Coronavirus crisis while supporting the UK’s next generation of cutting-edge start-ups – helping to build the businesses of tomorrow and propel their future prosperity.

Tricerion used the funding to secure theitsMobile App and Web Portal providing secure access to the digital proof of a citizen’s immunity passport.

Tricerion is working with the following companies – each experts in their own field – to deliver the concept: The Life Sciences Division Limited, Atomate Limited and Ubisecure Limited.

Schehrezade Davidson, CEO, Tricerion, said “The value of an immunity passport is defined by the digital trust it presents and which will accelerate the reopening of societies globally. We believe the use and simplicity of our authentication method – an image string, called a Neurographic password – will enable the easy uptake of our privacy first, secure by design solution.” Executive Chair, Innovate UK, Dr Ian Campbell, said: “Businesses from all over the UK have answered our call rapidly to meet the challenges we face today and in the future through the power of innovation. The ideas we have seen can truly make a significant impact on society, improve the lives of individuals, especially those in vulnerable groups and enable businesses to prosper in challenging circumstances.”

What is ImmucheX?

ImmucheX is a digital immunity passport and portal for vaccinations. ImmucheX has been designed with privacy first – enabling individuals to prove their vaccination status.